Shumin Yuan Xiufeng Hu Yanqiu Zhao Zibing Wang
10.3389/fimmu.2020.563622
Front Immunol
2020 Nov 6;11:563622.
b cells pd-1 immune checkpoint inhibitor immunotherapy non-small cell lung cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/33240259/
Adenocarcinoma of Lung / drug therapy Antibodies, Monoclonal, Humanized / administration & dosage B-Lymphocytes / metabolism Carcinoma, Non-Small-Cell Lung / drug therapy Immune Checkpoint Inhibitors / administration & dosage Lung Neoplasms / drug therapy Lymphoma, B-Cell, Marginal Zone / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors
Adenocarcinoma of Lung / drug therapy Antibodies, Monoclonal, Humanized / administration & dosage B-Lymphocytes / metabolism Carcinoma, Non-Small-Cell Lung / drug therapy Immune Checkpoint Inhibitors / administration & dosage Lung Neoplasms / drug therapy Lymphoma, B-Cell, Marginal Zone / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Case Reports Research Support, Non-U.S. Gov't Aged Antineoplastic Agents, Immunological / therapeutic use Antineoplastic Agents, Phytogenic / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bevacizumab / therapeutic use Carboplatin / therapeutic use Humans Immunologic Factors / therapeutic use Lenalidomide / therapeutic use Male Paclitaxel / therapeutic use Progression-Free Survival Rituximab / therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Antineoplastic Agents, Phytogenic Immune Checkpoint Inhibitors Immunologic Factors PDCD1 protein, human Programmed Cell Death 1 Receptor Bevacizumab Rituximab sintilimab Carboplatin Lenalidomide Paclitaxel
PMC7681247
33240259
Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
2020